AI can bring transformational medicines; India has incredible talent pool: Bristol Myers CEO
Synopsis
“We are building to be one of the fastest-growing companies by the end of the decade,” says Chris Boerner, CEO, Bristol Myers Squibb. In an exclusive interaction with ET Prime, Boerner discusses the company’s focus on AI, why it is an exciting time to be in the oncology space, and their growing presence in India.
Bristol Myers Squibb (BMS) CEO Christopher Boerner climbed to the top of his organisation just four months ago. Prior to that, he held a range of leadership roles. His stint coincides with what BMS describes as a “period of renewal” or a slow-growth phase until it sees a maximising performance from 2025. To fuel that rise, BMS has been on a deal-signing spree, bulking up on its oncology and neuroscience portfolios. On a visit to India to attend
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Uh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with
Minimal Ads
Comment & Engage with ET Prime community 
Exclusive invites to Virtual Events with Industry Leaders 
A trusted team of Journalists & Analysts who can best filter signal from noise 
Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-
